The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease (Q38206916)

31 August 2017

The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease (English)

1 reference

31 August 2017

1 reference

Jennifer Müller

1

1 reference

31 August 2017

Lars Nitschke

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

29 April 2014

1 reference

Nature Reviews Rheumatology

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

7

1 reference

31 August 2017

422-428

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.54

31 August 2017

0 references

cites work

Predominant autoantibody production by early human B cell precursors

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Siglecs and their roles in the immune system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

CD22 is a negative regulator of B-cell receptor signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

CD22 x Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

B cell defects in SLP65/BLNK-deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Interaction of CD22 with alpha2,6-linked sialoglycoconjugates: innate recognition of self to dampen B cell autoreactivity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

CD22 regulates thymus-independent responses and the lifespan of B cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-prone mice affects ligand binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Natural ligands of the B cell adhesion molecule CD22 beta can be masked by 9-O-acetylation of sialic acids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Functionally defective germline variants of sialic acid acetylesterase in autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Genetic susceptibility to SLE: recent progress from GWAS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

B cells: depletion or functional modulation in rheumatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Suppressing the antibody response with Siglec ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

C-4 modified sialosides enhance binding to Siglec-2 (CD22): towards potent Siglec inhibitors for immunoglycotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

The role of CD22 and other inhibitory co-receptors in B-cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.54

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24763061

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Receptor editing in self-reactive bone marrow B cells. The Journal of Experimental Medicine. 1993. 177: 1009-1020.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24763061

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2014.54

1 reference

Dimensions Publication ID

31 August 2017

0 references

1 reference